ストックスクリーナーアプリを入手
156.98
2.02%
3.11
アフターアワーズ：
157.06
0.08
+0.05%
前日終値:
$153.87
開ける：
$152.65
24時間の取引高:
571.84K
Relative Volume:
1.57
時価総額：
$4.54B
収益：
$290.51M
当期純損益:
$89.16M
株価収益率:
52.50
EPS:
2.99
ネットキャッシュフロー:
$119.18M
1週間 パフォーマンス:
+6.35%
1か月 パフォーマンス:
+12.93%
6か月 パフォーマンス:
-1.73%
1年 パフォーマンス:
-21.03%
1日の値動き範囲:
$151.75
$159.00
1週間の範囲:
$147.95
$159.00
52週間の値動き範囲:
$122.80
$207.84
Krystal Biotech Inc Stock (KRYS) Company Profile
名前
Krystal Biotech Inc
セクター
電話
(412) 586-5830
住所
2100 WHARTON STREET, PITTSBURGH, PA
KRYS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
156.98 | 4.45B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-05 | 開始されました | Jefferies | Buy |
| 2024-08-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 開始されました | Citigroup | Buy |
| 2023-09-07 | 開始されました | Berenberg | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2023-02-28 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-25 | ダウングレード | Goldman | Buy → Neutral |
| 2022-01-18 | 開始されました | BofA Securities | Buy |
| 2021-07-20 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-18 | 開始されました | B. Riley FBR | Buy |
| 2020-06-04 | 開始されました | Evercore ISI | Outperform |
| 2019-09-24 | 開始されました | Goldman | Neutral |
| 2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-24 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-06-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-30 | 開始されました | Guggenheim | Buy |
| 2018-09-11 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Krystal Biotech Inc (KRYS) 最新ニュース
Local biotech co-founder named to Forbes 50 Over 50 - The Business Journals
KRYSTAL BIOTECH Earnings Preview: Recent $KRYS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Earnings Outlook For Krystal Biotech - 富途牛牛
What are analysts’ price targets for Krystal Biotech Inc. in the next 12 monthsDaily Trading Opportunities For Consistent Profits - jammulinksnews.com
How does Krystal Biotech Inc. compare to its industry peersEarnings Report Growth Plan For Smart Trading - jammulinksnews.com
Why is Krystal Biotech Inc. stock attracting strong analyst attentionAI Powered Growth Plan From AI Tools - jammulinksnews.com
Quantitative breakdown of Krystal Biotech Inc. recent moveAlpha Driven Watchlist With Alerts Published - metal.it
How Krystal Biotech Inc. stock performs during market volatilityTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Why Krystal Biotech Inc. stock attracts strong analyst attentionWeekly Chart Analysis With Entry Advice Provided - metal.it
Why We're Not Concerned About Krystal Biotech, Inc.'s (NASDAQ:KRYS) Share Price - 富途牛牛
Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025 - The Manila Times
Will Krystal Biotech Inc. Recover After Recent DeclineIntraday Trend Analysis for Fast Gains Released - metal.it
What is the risk reward ratio of investing in Krystal Biotech Inc. stockAdvanced Screener Guidance With High Returns - jammulinksnews.com
Krystal Biotech receives regulatory approval to expand to Japan - The Business Journals
Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth - Yahoo Finance
Krystal Biotech’s Vyjuvek authorised in Japan to treat DEB - World Pharmaceutical Frontiers
What is the dividend policy of Krystal Biotech Inc. stockUnlock your portfolio’s hidden potential - jammulinksnews.com
How volatile is Krystal Biotech Inc. stock compared to the marketFree Stock Chart Pattern Guide - jammulinksnews.com
What catalysts could drive Krystal Biotech Inc. stock higher in 2025Post Market Outlook For Smart Trading - jammulinksnews.com
What makes Krystal Biotech Inc. stock price move sharplyUnlock exclusive stock market forecasts - jammulinksnews.com
Is Krystal Biotech Inc. stock overvalued or undervaluedUnlock your portfolio’s full growth potential - jammulinksnews.com
Krystal Biotech Retains 'Buy' Rating with $219 Price Target - AInvest
Krystal Biotech’s Subsidiary Reports Positive Phase 1 Results - The Globe and Mail
A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $192 to $240 - 富途牛牛
Krystal Biotech (KRYS) Retains 'Buy' Rating with $219 Price Targ - GuruFocus
What analysts say about Krystal Biotech Inc. stockSuperior returns - PrintWeekIndia
Positive Phase 1 Trial Results for KB304 Bolster Buy Rating for Krystal Biotech Amidst Promising Market Potential - TipRanks
Krystal Biotech Gains Approval for DEB Treatment in Japan - TipRanks
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa - The Manila Times
Krystal Biotech's VYJUVEK Receives Approval in Japan for Dystrophic Epidermolysis Bullosa Treatment from Birth - Quiver Quantitative
Is Krystal Biotech Inc. a good long term investmentFree Predictions - PrintWeekIndia
Revolutionary Genetic Treatment for Rare Skin Disease Gets Historic Japan Approval with Home Use Option - Stock Titan
What risks could impact Krystal Biotech Inc. stock performanceTremendous gains - jammulinksnews.com
Krystal Biotech’s Promising Aesthetic Developments and Positive Phase I Results Justify Buy Rating - TipRanks
What drives Krystal Biotech Inc. stock priceFree Wealth Management Insights - PrintWeekIndia
Jeune Announces Positive Results and Significant Aesthetic - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS), Abivax SA Sponsored ADR (ABVX) and Kyowa Kirin Co (OtherKYKOF) - The Globe and Mail
Phase 1 Trial Shows 100% Success Rate for Novel Décolleté Wrinkle Treatment | KRYS Stock News - Stock Titan
Krystal Biotech Inc. Stock Analysis and ForecastFree Stock Movement Tracking - jammulinksnews.com
Krystal Biotech (KRYS) Gets a Buy from Bank of America Securities - The Globe and Mail
Krystal Biotech price target lowered to $192 from $193 at BofA - TipRanks
Krystal Biotech Inc (KRYS) 財務データ
収益
当期純利益
現金流量
EPS
Krystal Biotech Inc (KRYS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Krishnan Suma | President, R&D |
Jul 14 '25 |
Sale |
150.30 |
13,400 |
2,014,015 |
1,512,529 |
| Krishnan Suma | President, R&D |
Jul 15 '25 |
Sale |
151.01 |
3,084 |
465,700 |
1,509,445 |
| Krishnan Suma | President, R&D |
Jul 15 '25 |
Sale |
150.98 |
3,036 |
458,361 |
1,440,240 |
| Krishnan Suma | President, R&D |
Jul 16 '25 |
Sale |
150.00 |
1,529 |
229,350 |
1,438,711 |
| Krishnan Suma | President, R&D |
Jul 16 '25 |
Sale |
150.00 |
1,389 |
208,350 |
1,508,056 |
| Krishnan Krish S | President and CEO |
Jul 14 '25 |
Sale |
150.30 |
13,435 |
2,019,225 |
1,443,276 |
| Krishnan Krish S | President and CEO |
Jul 14 '25 |
Sale |
150.30 |
13,400 |
2,014,015 |
1,512,529 |
| Krishnan Krish S | President and CEO |
Jul 15 '25 |
Sale |
151.01 |
3,084 |
465,700 |
1,509,445 |
| Krishnan Krish S | President and CEO |
Jul 15 '25 |
Sale |
150.98 |
3,036 |
458,361 |
1,440,240 |
| Krishnan Krish S | President and CEO |
Jul 16 '25 |
Sale |
150.00 |
1,529 |
229,350 |
1,438,711 |
0.93%
0.15%
大文字化:
|
ボリューム (24 時間):